Toll Free: 1-888-928-9744

Influenza B Infections - Pipeline Review, H2 2016

Published: Jul, 2016 | Pages: 71 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Influenza B Infections - Pipeline Review, H2 2016

Summary

Global Markets Direct's, 'Influenza B Infections - Pipeline Review, H2 2016', provides an overview of the Influenza B Infections pipeline landscape. 

The report provides comprehensive information on the therapeutics under development for Influenza B Infections, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Influenza B Infections and features dormant and discontinued projects. 

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Influenza B Infections
- The report reviews pipeline therapeutics for Influenza B Infections by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved Influenza B Infections therapeutics and enlists all their major and minor projects
- The report assesses Influenza B Infections therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news related to pipeline therapeutics for Influenza B Infections

Reasons To Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand important and diverse types of therapeutics under development for Influenza B Infections
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding  Influenza B Infections pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
 Table of Contents
Table of Contents 2 List of Tables 5 List of Figures 6 Introduction 7 Global Markets Direct Report Coverage 7 Influenza B Infections Overview 8 Therapeutics Development 9 Pipeline Products for Influenza B Infections - Overview 9 Pipeline Products for Influenza B Infections - Comparative Analysis 10 Influenza B Infections - Therapeutics under Development by Companies 11 Influenza B Infections - Therapeutics under Investigation by Universities/Institutes 12 Influenza B Infections - Pipeline Products Glance 13 Late Stage Products 13 Clinical Stage Products 14 Early Stage Products 15 Influenza B Infections - Products under Development by Companies 16 Influenza B Infections - Products under Investigation by Universities/Institutes 17 Influenza B Infections - Companies Involved in Therapeutics Development 18 AbbVie Inc. 18 Altravax, Inc. 19 Aphios Corporation 20 BioClonetics Immunotherapeutics, Inc. 21 ContraFect Corporation 22 Humabs BioMed SA 23 Johnson & Johnson 24 Medicago Inc. 25 MedImmune, LLC 26 Mucosis B.V. 27 Sanofi Pasteur SA 28 Vaxart, Inc. 29 Zydus Cadila Healthcare Limited 30 Influenza B Infections - Therapeutics Assessment 31 Assessment by Monotherapy Products 31 Assessment by Combination Products 32 Assessment by Target 33 Assessment by Mechanism of Action 35 Assessment by Route of Administration 36 Assessment by Molecule Type 38 Drug Profiles 40 AL-18 - Drug Profile 40 Product Description 40 Mechanism Of Action 40 R&D Progress 40 APP-0205 - Drug Profile 41 Product Description 41 Mechanism Of Action 41 R&D Progress 41 APP-309 - Drug Profile 42 Product Description 42 Mechanism Of Action 42 R&D Progress 42 CF-403 - Drug Profile 43 Product Description 43 Mechanism Of Action 43 R&D Progress 43 CR-8033 - Drug Profile 44 Product Description 44 Mechanism Of Action 44 R&D Progress 44 CR-8071 - Drug Profile 45 Product Description 45 Mechanism Of Action 45 R&D Progress 45 CR-9114 - Drug Profile 46 Product Description 46 Mechanism Of Action 46 R&D Progress 46 Fluad (quadrivalent) - Drug Profile 47 Product Description 47 Mechanism Of Action 47 R&D Progress 47 FluGEM - Drug Profile 48 Product Description 48 Mechanism Of Action 48 R&D Progress 48 influenza [serotype B] vaccine - Drug Profile 49 Product Description 49 Mechanism Of Action 49 R&D Progress 49 influenza [serotypes A, B] (split virion, tetravalent) vaccine - Drug Profile 50 Product Description 50 Mechanism Of Action 50 R&D Progress 50 influenza [serotypes A, B] (virus like particle) vaccine - Drug Profile 51 Product Description 51 Mechanism Of Action 51 R&D Progress 51 influenza [strains A/H1N1 + A/H3N2 + B/Victoria + B/Yamagata] (quadrivalent) vaccine - Drug Profile 52 Product Description 52 Mechanism Of Action 52 R&D Progress 52 influenza [strains A/H1N1 + A/H3N2 + B/Victoria + B/Yamagata] (tetravalent, split virion) vaccine - Drug Profile 53 Product Description 53 Mechanism Of Action 53 R&D Progress 53 influenza [strains A/H1N1 + A/H3N2 + B/Yamagata + B/Victoria] (quadrivalent) vaccine - Drug Profile 54 Product Description 54 Mechanism Of Action 54 R&D Progress 54 influenza [strains A/H1N1 + A/H3N2 + B/Yamagata + B/Victoria] (quadrivalent, virus like particle) vaccine - Drug Profile 55 Product Description 55 Mechanism Of Action 55 R&D Progress 55 influenza [strains A/H1N1 + A/H3N2 + B/Yamagata] (trivalent, split virion) vaccine - Drug Profile 58 Product Description 58 Mechanism Of Action 58 R&D Progress 58 influenza [strains A/H1N1 + A/H3N2 + B/Yamagata] (trivalent, virus like particle) vaccine - Drug Profile 59 Product Description 59 Mechanism Of Action 59 R&D Progress 59 influenza [strains A/H1N1 + A/H3N2 + B] (quadrivalent) vaccine - Drug Profile 60 Product Description 60 Mechanism Of Action 60 R&D Progress 60 influenza [strains A/H1N1 + A/H3N2 + B] (trivalent, split virion) vaccine - Drug Profile 61 Product Description 61 Mechanism Of Action 61 R&D Progress 61 influenza [strains A/H1N1 + A/H3N2 + B] (trivalent, split virion) vaccine - Drug Profile 62 Product Description 62 Mechanism Of Action 62 R&D Progress 62 Monoclonal Antibody for Influenza B - Drug Profile 63 Product Description 63 Mechanism Of Action 63 R&D Progress 63 Monoclonal Antibody for Influenza B Infections - Drug Profile 64 Product Description 64 Mechanism Of Action 64 R&D Progress 64 VXABYW-10 - Drug Profile 65 Product Description 65 Mechanism Of Action 65 R&D Progress 65 Influenza B Infections - Dormant Projects 66 Influenza B Infections - Discontinued Products 67 Influenza B Infections - Product Development Milestones 68 Featured News & Press Releases 68 Dec 17, 2015: Vaxart Announces Enrollment of First Patient in Influenza B Phase 1 Trial 68 Mar 11, 2011: Sanofi Pasteur And Daiichi Sankyo Announce Voluntary Recall Of Hemophilus Influenza Type B Conjugate Vaccine 69 Apr 23, 1993: FDA Approval of Use of a New Haemophilus b Conjugate Vaccine and a Combined Diphtheria-Tetanus-Pertussis and Haemophilus b Conjugate Vaccine for Infants and Children 69 Appendix 70 Methodology 70 Coverage 70 Secondary Research 70 Primary Research 70 Expert Panel Validation 70 Contact Us 70 Disclaimer 71
List of Tables
Number of Products under Development for Influenza B Infections, H2 2016 9 Number of Products under Development for Influenza B Infections - Comparative Analysis, H2 2016 10 Number of Products under Development by Companies, H2 2016 11 Number of Products under Investigation by Universities/Institutes, H2 2016 12 Comparative Analysis by Late Stage Development, H2 2016 13 Comparative Analysis by Clinical Stage Development, H2 2016 14 Comparative Analysis by Early Stage Development, H2 2016 15 Products under Development by Companies, H2 2016 16 Products under Investigation by Universities/Institutes, H2 2016 17 Influenza B Infections - Pipeline by AbbVie Inc., H2 2016 18 Influenza B Infections - Pipeline by Altravax, Inc., H2 2016 19 Influenza B Infections - Pipeline by Aphios Corporation, H2 2016 20 Influenza B Infections - Pipeline by BioClonetics Immunotherapeutics, Inc., H2 2016 21 Influenza B Infections - Pipeline by ContraFect Corporation, H2 2016 22 Influenza B Infections - Pipeline by Humabs BioMed SA, H2 2016 23 Influenza B Infections - Pipeline by Johnson & Johnson, H2 2016 24 Influenza B Infections - Pipeline by Medicago Inc., H2 2016 25 Influenza B Infections - Pipeline by MedImmune, LLC, H2 2016 26 Influenza B Infections - Pipeline by Mucosis B.V., H2 2016 27 Influenza B Infections - Pipeline by Sanofi Pasteur SA, H2 2016 28 Influenza B Infections - Pipeline by Vaxart, Inc., H2 2016 29 Influenza B Infections - Pipeline by Zydus Cadila Healthcare Limited, H2 2016 30 Assessment by Monotherapy Products, H2 2016 31 Assessment by Combination Products, H2 2016 32 Number of Products by Stage and Target, H2 2016 34 Number of Products by Stage and Mechanism of Action, H2 2016 35 Number of Products by Stage and Route of Administration, H2 2016 37 Number of Products by Stage and Molecule Type, H2 2016 39 Influenza B Infections - Dormant Projects, H2 2016 66 Influenza B Infections - Discontinued Products, H2 2016 67



To request a free sample copy of this report, please complete the form below.

We never share your personal data. Privacy policy
Interested in this report? Get your FREE sample now! Get a Free Sample
Choose License Type
Single User - US $2000
Multi User - US $4000
Hexareeasearch Know

Did you know?

Research Assistance

Phone: 1-415-349-0054

Toll Free: 1-888-928-9744

Email: [email protected]

Why to buy from us

Custom research service

Speak to the report author to design an exclusive study to serve your research needs.

Information security

Your personal and confidential information is safe and secure.

verify